Spero Therapeutics licenses anti-CD40L antibody SP001 from Innovent in deal worth about US$ 1.1 billion

Spero Therapeutics, Inc.

Spero Therapeutics, Inc.

SPRO

0.00
  • Spero Therapeutics signed an exclusive license with Innovent Biologics for SP001 (IBI355), a Phase 2-ready third-generation anti-CD40L antibody.
  • Spero secured global rights excluding Greater China, covering development, manufacturing, research, and commercialization.
  • Innovent will receive an upfront payment, up to USD 1.1 billion in milestones, and tiered royalties on net sales in Spero’s territories.
  • Spero plans to start a Phase 2 trial in IgG4-related disease in Q2 2027.
  • Innovent plans a China Phase 2 trial in Sjögren’s disease by early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.